Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27928913 | 0.84 | SCN9A (0.40) | ACACBSCN9ALMNACYP2C9TSHR | |
| SCHEMBL28051945 | 0.83 | LMNA (0.47) | ACACBSCN9ALMNACYP2C9TSHR | |
| SCHEMBL17430824 | 0.81 | SCN9A (0.39) | ACACBSCN9ALMNACYP2C9TSHR | |
| SCHEMBL17432902 | 0.80 | TRPM8 (0.37) | ACACBTRPM8 | |
| SCHEMBL15599222 | 0.78 | S1PR1 (0.38) | ACACBSCN9ALMNACYP2C9TSHR | |
| SCHEMBL9379161 | 0.76 | S1PR1 (0.37) | ACACBSCN9ALMNACYP2C9TSHR | |
| SCHEMBL364199 | 0.76 | SCN9A (0.41) | ACACBSCN9ALMNACYP2C9TSHR | |
| SCHEMBL1293363 | 0.76 | PLAU (0.39) | ACACBSCN9ALMNACYP2C9TSHR | |
| SCHEMBL13791681 | 0.76 | NPSR1 (0.40) | TRPM8 | |
| SCHEMBL13678329 | 0.76 | RORC (0.40) | ACACBSCN9ALMNACYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854782-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2017172802-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-9550775-B2 | Substituted triazolopyridines and methods of use thereof | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | P2RX3, P2RX1, P2RX4 | ACACB 4750/4885SCN9A 1460/4885LMNA 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.